Cardiac biointerventions: whatever happened to stem cell and gene therapy? Review uri icon

Overview

MeSH

  • Humans

MeSH Major

  • Genetic Therapy
  • Heart Diseases
  • Stem Cell Transplantation

abstract

  • Angiogenic gene therapy and stem cell administration represent two "biologic" interventions for the treatment of cardiac disease that were first introduced more than 15 years ago but still have not achieved approval for clinical use for the treatment of myocardial ischemia and heart failure. Challenges that have been encountered in the clinical testing of these new treatment strategies have included a lack of placebo controls in phase I surgical trials and the incorporation of potentially ineffectual agent delivery via intracoronary routes. Although enthusiasm for these approaches may therefore have ebbed, new refinements in these technologies and insights into their appropriate clinical testing suggest that a resurgence of interest in these "biointerventions" may be expected in the near future.

publication date

  • June 2012
  • May 2012

has subject area

  • Genetic Therapy
  • Heart Diseases
  • Humans
  • Stem Cell Transplantation

Research

keywords

  • Journal Article
  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/IMI.0b013e318265d9f6

PubMed ID

  • 22885457

Additional Document Info

start page

  • 173

end page

  • 179

volume

  • 7

number

  • 3